Hims & Hers Health, Inc. (HIMS) Fair Value 2026

HIMS · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.9 /10

32 fundamental signals · 8 models active

Value Trap Risk

LOW (31/100)

Quick Summary — As of 2026-08-28, Hims & Hers Health, Inc. (HIMS) trades at $28.84, versus a $5.56 median fair value across its 8 active models — 80.7% below the current price. QOC: 7.9/10. Value Trap Risk: 31/100 (LOW). 8/13 models active. Within that set, the Bayesian DCF component alone returns $5.48.

Key Facts

Ticker
HIMS
Price
$28.84
Quality Score
7.9/10
Value Trap Risk
31/100
Models Active
8/13
Last Updated
Strength: 8 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Hims & Hers Health, Inc. (HIMS) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Hims & Hers Health, Inc. (HIMS) appears overvalued as of : the median of 8 independent fair value estimates is $5.56, 80.7% below the current price of $28.84. Estimates range from $2.65 to $11.68. HIMS scores 7.9/10 on fundamental quality and 31/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. HIMS’s -80.7% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Hims & Hers Health, Inc. Stock in 2026? →

What Fair Value Does Each Model Give HIMS?

8 Intrinsic Value Models vs. Current Price ($28.84)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $5.48 -81.0%
Ensemble · Low Conviction
 $5.55 -80.7%
Scenario · High Conviction
 $7.44 -74.2%
Intrinsic · High Conviction
 $3.00 -89.6%
Unlock the Full Matrix

Access 4 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is HIMS's Fair Value Range?

Spread across 8 independent models · $2.65 to $11.68

CirclFi's 8 active models place Hims & Hers Health, Inc. (HIMS) between $2.65 and $11.68 per share, a spread of 163% of the median. The median of that range — $5.56 — is the fair value CirclFi publishes for HIMS, against a current price of $28.84.

Low · EROICHigh · Regime Cross
$2.65median $5.56$11.68
Where the range comes from
Most bearish modelEROIC Spread$2.65
Most bullish modelRegime Cross-Sectional$11.68
Model agreement0 bullish · 8 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for HIMS. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on HIMS, not a CirclFi price target. How each model works →

What Is Hims & Hers Health, Inc. (HIMS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Hims & Hers Health, Inc.'s intrinsic value is estimated at $5.56, suggesting the stock is overvalued at its current price of $28.84. With 8 out of 8 models flagging downside (-80.7% vs price), the market may be pricing in unsustainable growth. Model dispersion is worth noting: Regime Cross targets $11.68 (-59.5%), versus EROIC at $2.65 (-90.8%). This +31.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About HIMS?

8 of 13 models are currently active for HIMS. All 8 active models suggest the stock trades above fair value. Taken together, their median fair value for HIMS is $5.56 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $5.48 on its own, implying -81.0% downside from the current price. See which stocks rank higher →

How Does HIMS Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, HIMS ranks #21 by Quality of Company score. CirclFi's QOC score of 7.9/10 evaluates 32 fundamental signals. A score of 7.9 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a biopharma enterprise, Hims & Hers Health, Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating HIMS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is HIMS a Value Trap?

CirclFi's Value Trap algorithm assigns HIMS a score of 31/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Hims & Hers Health, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Hims & Hers Health, Inc.'s fundamental quality profile registers 7.9/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +31.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HIMS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HIMS's 8 active models, average confidence is 43%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Hims & Hers Health, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

XERSXeris Biopharma Holdings, Inc.QOC 7.9PCRXPacira BioSciences, Inc.QOC 7.8ORGOOrganogenesis Holdings Inc.QOC 8.0CRONCronos Group Inc.QOC 7.4KNSAKiniksa Pharmaceuticals International, plcQOC 8.1TRLVTrulieve Cannabis Corp.QOC 7.3EOLSEvolus, Inc.QOC 6.2NTRRNeutra Corp.QOC 5.1CTTHCTT Pharmaceutical Holdings, Inc.QOC 3.3UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: XERS · PCRX · ORGO · CRON · KNSA · TRLV · EOLS · NTRR · CTTH · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to HIMS?

7 companies across all industries closest to HIMS’s Quality of Company score of 7.9/10.

LEGLeggett & Platt, IncorporatedQOC 7.9HLITHarmonic Inc.QOC 7.9SFSTSouthern First Bancshares, Inc.QOC 7.9SODISolitron Devices, Inc.QOC 7.9LIVELive Ventures IncorporatedQOC 7.9GLPIGaming and Leisure Properties, Inc.QOC 7.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LEG · HLIT · SFST · SODI · LIVE · GLPI · NVDA

Where Does HIMS Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

HIMS is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Hims & Hers Health, Inc.’s Valuation?

What is Hims & Hers Health, Inc.'s intrinsic value in 2026?

CirclFi puts Hims & Hers Health, Inc. (HIMS)'s intrinsic value at $5.56 — the median of 8 independent model estimates as of 2026-08-28, ranging from $2.65 to $11.68. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $5.48 on its own. The Quality of Company score is 7.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HIMS overvalued or undervalued right now?

At $28.84, 0 of 8 active models suggest HIMS may be undervalued, while 8 indicate potential overvaluation. The median of all 8 fair value estimates is $5.56, 80.7% below the current price of $28.84 — a consensus view that HIMS is overvalued. The assessment depends on which methodology best fits Hims & Hers Health, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 7.9 mean for HIMS?

Hims & Hers Health, Inc.'s QOC of 7.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on HIMS?

CirclFi analyzes HIMS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on HIMS?

Of the 8 models currently active on HIMS, Regime Cross-Sectional is the most bullish at $11.68 per share, and EROIC Spread is the most bearish at $2.65. CirclFi's published fair value for HIMS is the median of that range, $5.56, not either extreme. The gap between the two ends equals 163% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is HIMS a value trap in 2026?

Hims & Hers Health, Inc.'s Value Trap score is 31/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Hims & Hers Health, Inc. (HIMS) has a median fair value of $5.56 — 80.7% below the current price of $28.84 — as of 2026-08-28.” Source: circlfi.com/stock/HIMS/ · Methodology
Primary sources for this HIMS valuation
  • Financial statements: Hims & Hers Health, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001773751) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HIMS as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on HIMS.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for HIMS Unlock All 8 — $39/mo